Sanchez-Russo et al., 2022 - Google Patents
The gut and kidney crosstalk in immunoglobulin A nephropathySanchez-Russo et al., 2022
View HTML- Document ID
- 280874121616904904
- Author
- Sanchez-Russo L
- Rajasekaran A
- Bin S
- Faith J
- Cravedi P
- Publication year
- Publication venue
- Kidney360
External Links
Snippet
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. The working model for the pathogenesis of IgAN involves a multistep process starting from the production of galactose-deficient and polymeric immunoglobulin A-1 (gd …
- 208000010159 IGA Glomerulonephritis 0 title abstract description 134
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klomjit et al. | COVID-19 vaccination and glomerulonephritis | |
| Zhang et al. | The gut microbiota: emerging evidence in autoimmune diseases | |
| Gesualdo et al. | The mucosal immune system and IgA nephropathy | |
| Sanchez-Russo et al. | The gut and kidney crosstalk in immunoglobulin A nephropathy | |
| Qiu et al. | Triggers of autoimmunity: the role of bacterial infections in the extracellular exposure of lupus nuclear autoantigens | |
| US20220184196A1 (en) | Methods and compositions for treating and diagnosing autoimmune diseases | |
| Catrina et al. | Mechanisms involved in triggering rheumatoid arthritis | |
| Eleftheriou et al. | Management of Kawasaki disease | |
| Marks et al. | Innate immunity in inflammatory bowel disease: a disease hypothesis | |
| He et al. | Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies | |
| Desai et al. | Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review | |
| Mewar et al. | Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors | |
| Li et al. | Role of intestinal microbiota on gut homeostasis and rheumatoid arthritis | |
| Davidson et al. | Lupus nephritis: lessons from murine models | |
| Ehren et al. | Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy—short version of the updated German best practice guideline (S2e)—AWMF register no. 166-001, 6/2020 | |
| Hoxha et al. | The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study | |
| Uibo et al. | Primary biliary cirrhosis: a multi‐faced interactive disease involving genetics, environment and the immune response | |
| Bar-Yoseph et al. | Infliximab–tumor necrosis factor complexes elicit formation of anti-drug antibodies | |
| Chun et al. | Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis | |
| Koprivsek et al. | Evasion of innate lymphoid cell-regulated gamma interferon responses by Chlamydia muridarum to achieve long-lasting colonization in mouse colon | |
| McKay et al. | Therapeutic trials in difficult to treat steroid sensitive nephrotic syndrome: challenges and future directions | |
| Zandvliet et al. | Monitoring antigen-specific biologics: current knowledge and future prospects | |
| Volzke et al. | Inflammatory joint disease is a risk factor for streptococcal sepsis and septic arthritis in mice | |
| Gu et al. | Experimental antiglomerular basement membrane GN induced by a peptide from actinomyces | |
| Buch | Sequential use of biologic therapy in rheumatoid arthritis |